NCT05960708View on ClinicalTrials.gov

A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

September 13, 2024

Study Completion Date

September 13, 2024

Conditions
Allergic DiseaseChronic Spontaneous UrticariaChronic Inducible UrticariaCold Urticaria
Interventions
DRUG

YH35324

Subcutaneous injection of YH35324

DRUG

Omalizumab

Subcutaneous injection of Omalizumab

DRUG

Placebo

Subcutaneous injection of None of active ingredient

Trial Locations (9)

13496

CHA Bundang Medical Center, Seongnam-si

13620

Seoul National University Bundang Hospital, Seongnam-si

14068

Hallym University Sacred Heart Hospital, Anyang-si

16499

Ajou University Hospital, Suwon

18450

Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si

49201

Dong-a University hospital, Busan

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06591

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT05960708 - A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases | Biotech Hunter | Biotech Hunter